EMERGENCY OVERVIEW
Each Ribavirin Tablets intended for oral administration contains Ribavirin and excipients generally considered to be non-toxic and non-hazardous in small quantities and under conditions of normal occupational exposure.

Section 1. Identification

Identification of the product

Product name: Ribaverin Tablets
Formula: C₈H₁₂N₄O₅
Chemical Name: 1-ß-D-ribofuranosyl- 1 H-1,2,4-triazole-3-carboxamide

Manufacturer / supplier identification

Company: Cadila Healthcare Ltd. Ahmedabad, India
Contact for information: Tel.: +91 79 6868100  Fax: +91 79 3750319
Emergency Telephone No. Tel.: +91 79 6868100

Recommended use / Therapeutic Category A nucleoside analogue with antiviral activity.

Restriction on Use / Contraindications Ribavirin tablet is contraindicated in:
• Patients with known hypersensitivity to ribavirin tablets or to any component of the tablet.
• Women who are pregnant.
• Men whose female partners are pregnant.
Section 2. Hazard(s) Information

Dose and Administration
The daily dose of ribavirin tablet is 800 mg to 1200 mg administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics, response to therapy, and tolerability of the regimen.

Adverse Effects
The most common life-threatening or fatal events induced or aggravated by peginterferon alfa-2a and ribavirin tablets were depression, suicide, relapse of drug abuse/overdose, and bacterial infections.

In all studies, one or more serious adverse reactions occurred in 10% of CHC monoinfected patients receiving peginterferon alfa-2a alone or in combination with ribavirin tablets.

The most common serious adverse event (3% in CHC) was bacterial infection (e.g., sepsis, osteomyelitis, endocarditis, pyelonephritis, pneumonia).

Over Dose Effect
No cases of overdose with ribavirin tablets have been reported in clinical trials.

Medical Conditions
Birth defects and fetal death with ribavirin: Patients must have a negative pregnancy test prior to therapy; use at least 2 forms of contraception and undergo monthly pregnancy tests.

Patients exhibiting the following conditions should be closely monitored and may require dose reduction or discontinuation of therapy:

- Monotherapy with ribavirin is not permitted.
- Hemolytic anemia may occur with a significant initial drop in hemoglobin.
- Pancreatitis.
- Pulmonary infiltrates or pulmonary function impairment.
- New or worsening ophthalmologic disorders
- Severe decreases in neutrophil and platelet counts, and hematologic, endocrine (e.g., TSH), and hepatic abnormalities.
- Dental/periodontal disorders reported with combination therapy.
- Weight loss and growth inhibition reported during combination therapy in pediatric patients. Long-term growth inhibition (height) reported in some patients.

Contraindications
Ribavirin tablet is contraindicated in:
- Patients with known hypersensitivity to ribavirin tablets or to any component of the tablet.
Pregnancy Comments

Ribavirin may cause birth defects and/or death of the exposed fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin has demonstrated significant teratogenic and/or embryocidal effects in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin.

RIBAVIRIN TABLETS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO PLANNED INITIATION OF THERAPY.

Pregnancy Category

X

Section 3. Composition / information on ingredients

<table>
<thead>
<tr>
<th>Component</th>
<th>Exposure Limit</th>
<th>CAS No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Principle Component:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ribavirin</td>
<td>Not Found</td>
<td>36791-04-5</td>
</tr>
<tr>
<td><strong>Inactive Ingredients:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crospovidone,</td>
<td>Not Found</td>
<td>9003-39-8</td>
</tr>
<tr>
<td>Hypromellose,</td>
<td>Not Found</td>
<td>9004-65-3</td>
</tr>
<tr>
<td>Iron oxide red</td>
<td>Not Found</td>
<td>51274-00-1</td>
</tr>
<tr>
<td>Iron oxide yellow</td>
<td>Not Found</td>
<td>51274-00-1</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>Not Found</td>
<td>9004-34-6</td>
</tr>
<tr>
<td>Polyethylene glycol</td>
<td>Not Found</td>
<td>25322-68-3</td>
</tr>
<tr>
<td>Povidone</td>
<td>Not Found</td>
<td>9003-39-8</td>
</tr>
<tr>
<td>Silicon dioxide</td>
<td>Not Found</td>
<td>7621-86-9</td>
</tr>
<tr>
<td>Talc</td>
<td>Not Found</td>
<td>14807-96-6</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>Not Found</td>
<td>13463-67-7</td>
</tr>
</tbody>
</table>
Section 4. First-aid measures

General
Remove from exposure. Remove contaminated Clothing. Person developing serious hypersensitivity reaction must receive medical attention.

Overdose Treatment
No case of overdose

Section 5. Fire-fighting measures

Flash point Not Found
Auto-Ignition Temperature: Not Found
Extinguishing Media Water Spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and material.
Fire and Explosion Hazard This material is assumed to be combustible. As with all dry powders it is advisable to ground mechanical equipment in contact with the dry material to dissipate the potential build-up of static electricity.

Fire Fighting Procedure As with all fires, evacuate personnel to a safe area. Fire fighter should use self-contained breathing equipment and protective clothing.

Section 6. Accidental Release Measures

Spill Response Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labelled container for disposal. Wash spill site.

Section 7. Handling and Storage

Storage Store at 20° to 25°C (68° to 77°F). Keep bottle tightly closed.
Incompatibilities: No data available.

Section 8. Exposure controls / personal protection

Respiratory Protection Protection from inhalation is not normally necessary. If ventilation is inadequate or dust is likely to generate, use of suitable dust mask would be appropriate.
Skin Protection: Skin protection is not normally necessary, however it is good practice to avoid contact with chemical to use suitable gloves when handling.

Eye protection: Eye protection is not normally necessary. If concerned wear protective goggles or glasses. Wash hands prior to touching eye and in particular handling contact lenses.

Protective Clothing: Protective clothing is not normally necessary, however it is good practice to use apron.

Engineering Control: Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants below the exposure limit.

Section 9. Physical and chemical properties

Appearance: Ribavirin Tablets, 200 mg are light pink to pink, round, biconvex, beveled, film-coated tablets debossed with the logo of ‘ZC19’ on one side, other side plain.

Solubility in water: No Data Available

Boiling point: No Data Available

Evaporation rate: No Data Available

Reactivity in water: No Data Available

% Volatile by volume: No Data Available

Specific gravity: No Data Available

Vapour pressure: No Data Available

Other information: The molecular formula of Ribavirin is CsH12N4O5 and the molecular weight is 244.2. Ribavirin is a white crystalline powder. It is freely soluble in water and slightly soluble in anhydrous alcohol. Ribavirin tablet is available as a light pink to pink, round, biconvex, beveled, film-coated tablet for oral administration.

Section 10. Stability and Reactivity

Condition to avoid: Avoid exposure to extreme heat, light and moisture.

Decomposition Products: No Data Available

Incompatibilities: No Data available.

Section 11. Toxicological information

General: Handling of formulated product is not expected to cause any toxicological affects. The data pertains to the ingredient in formulations, rather than this...
Safety Data Sheet
RIBAVIRINTABLETS

Strength: 200mg. Pack Size: 168 Tablets per bottle Revision No.: 02

specie formulation.

Target organ
Eye contact, Skin contact and inhalation is not great risk as this product is tablet.

Other
The primary clinical toxicity of ribavirin is hemolytic anemia. The anemia associated with ribavirin therapy may result in worsening of cardiac disease that has led to fatal and nonfatal myocardial infarctions.

Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. In addition, ribavirin has a multiple dose half-life of 12 days, and it may persist in non-plasma compartments for as long as 6 months.

Section 12. Ecological information

Do not allow product to enter drinking water supplies, waste water or soil

Section 13. Disposal Consideration

Dispose the waste in accordance with all applicable Federal, State and local laws.

Section 14. Transport Information

The product is not hazardous when shipping via air (IATA), ground (DOT), or sea (IMDG).

Section 15. Regulatory Information

Generic Medicine. Approved by USFDA & the ANDA Number is 77-094

Section 16. Other information

None

Date of issue: 28/05/2015 Supersedes edition of: 01

The information contained herein is based on the state of our knowledge. It characterises the product with regard to the appropriate safety precautions. It does not represent a guarantee of the properties of the product.